share_log

Novavax | 8-K: Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights

Novavax | 8-K: Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights

诺瓦瓦克斯医药 | 8-K:Novavax 公布2024年第二季度财务业绩和运营亮点
美股SEC公告 ·  08/08 20:09

Moomoo AI 已提取核心信息

On August 8, 2024, Novavax, Inc. reported its financial results for the second quarter ended June 30, 2024. The company announced total revenue of $415 million for the quarter and ended the period with $1.1 billion in cash. Novavax has filed for authorization of its updated 2024-2025 COVID-19 vaccine with the U.S. FDA and EMA and has received a significant upfront payment and equity investment from Sanofi as part of a collaboration agreement. The company is also preparing for Phase 3 trials for its COVID-19-Influenza Combination and standalone influenza vaccines, expected to begin in Q4 2024. Novavax has implemented a cost reduction program, resulting in a 34% reduction in combined R&D and SG&A expenses compared to the same period in 2023. The company expects to deliver its updated COVID-19 vaccine by the start of the 2024-2025 vaccination season and has submitted an EUA amendment to the FDA. Novavax's financial guidance for the full year 2024 reflects total revenue between $700 million and $800 million, with combined R&D and SG&A expenses remaining between $700 million and $750 million.
On August 8, 2024, Novavax, Inc. reported its financial results for the second quarter ended June 30, 2024. The company announced total revenue of $415 million for the quarter and ended the period with $1.1 billion in cash. Novavax has filed for authorization of its updated 2024-2025 COVID-19 vaccine with the U.S. FDA and EMA and has received a significant upfront payment and equity investment from Sanofi as part of a collaboration agreement. The company is also preparing for Phase 3 trials for its COVID-19-Influenza Combination and standalone influenza vaccines, expected to begin in Q4 2024. Novavax has implemented a cost reduction program, resulting in a 34% reduction in combined R&D and SG&A expenses compared to the same period in 2023. The company expects to deliver its updated COVID-19 vaccine by the start of the 2024-2025 vaccination season and has submitted an EUA amendment to the FDA. Novavax's financial guidance for the full year 2024 reflects total revenue between $700 million and $800 million, with combined R&D and SG&A expenses remaining between $700 million and $750 million.
2024年8月8日,诺瓦瓦克斯医药公司公布了截至2024年6月30日第二季度的财务业绩报告。公司宣布本季度营业收入为4.15亿美元,并以11亿美元的现金收官。诺瓦瓦克斯新冠疫苗已向美国FDA和EMA申请更新版本授权,并已与赛诺菲安万特签订合作协议收取了重要的首付款和股权投资。公司还准备在2024年第四季度开始进行新冠-流感联合疫苗和独立流感疫苗的第三阶段试验。诺瓦瓦克斯实施了成本削减计划,使联合研发(R&D)和销售总管理费用(SG&A)在与2023年同期相比下降了34%。公司预计将在2024-2025年接种季节开始时提供更新的COVID-19疫苗并向FDA提出紧急使用授权(EUA)修正声明。诺瓦瓦克斯2024年的财务指导反映了总营业收入在7-8亿美元之间,联合R&D和SG&A费用保持在7-7.50亿美元之间。
2024年8月8日,诺瓦瓦克斯医药公司公布了截至2024年6月30日第二季度的财务业绩报告。公司宣布本季度营业收入为4.15亿美元,并以11亿美元的现金收官。诺瓦瓦克斯新冠疫苗已向美国FDA和EMA申请更新版本授权,并已与赛诺菲安万特签订合作协议收取了重要的首付款和股权投资。公司还准备在2024年第四季度开始进行新冠-流感联合疫苗和独立流感疫苗的第三阶段试验。诺瓦瓦克斯实施了成本削减计划,使联合研发(R&D)和销售总管理费用(SG&A)在与2023年同期相比下降了34%。公司预计将在2024-2025年接种季节开始时提供更新的COVID-19疫苗并向FDA提出紧急使用授权(EUA)修正声明。诺瓦瓦克斯2024年的财务指导反映了总营业收入在7-8亿美元之间,联合R&D和SG&A费用保持在7-7.50亿美元之间。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息